Drugs / Syndros
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | SYNDROS | — | 2016-07-01 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03661892 | Dec 2018 → Oct 2020 | breast cancer, metastatic carcinoma in the bone | University of Arizona | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Syndros | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03661892 ↗ |
| Route | Oral | “All patients start on Syndros at 4.2 mg po BID for 3 days” NCT03661892 ↗ |